Perioperative β-blocker therapy has been advocated to reduce cardiac mortality and morbidity in high-risk cardiac patients undergoing non-cardiac surgery. Core data that supported this intervention and informed international societal guidelines has recently been withdrawn. A subsequent meta-analysis of the remaining data reporting excess mortality has re-opened the debate about the utility of β-blocker therapy in the perioperative period. Criticism of remaining trial designs and new insights into the protective mechanisms of β-blocker therapy in critical illness raise important questions that should now be addressed by a further robust, high-quality randomised control trial.
Introduction
The systemic infl ammatory response associated with major surgery is well characterised and impacts on outcome in the perioperative period. This is particularly apparent in those patients who suffer signifi cant systemic co-morbidity who present for major surgery. This group, termed the 'high-risk surgical population', are relatively small in absolute numbers but account for the majority of the morbidity and mortality in the perioperative period. 1 Cardiopulmonary insuffi ciency is considered an important determinant of outcome, and much attention in recent times has focused on cardiac protection and optimisation in the perioperative period.
The Multicenter Study of Perioperative Ischemia of 1996 (McSPI, 1996) 2 and the later Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group I (DECREASE I, 1999) 3 were the fi rst trials to demonstrate the value of β-blockers in the perioperative period. Both trials demonstrated a reduced cardiovascular morbidity and mortality in populations of high-risk patients undergoing non-cardiac surgery.
The McSPI trial investigated the intervention of atenolol in non-cardiac surgical patients with known coronary artery disease; it randomised them to placebo or intravenous atenolol, ABSTRACT pre-induction of anaesthesia. The intervention, which was continued for 7 days postoperatively, was associated with a signifi cant reduction in all-cause mortality at 2 years and a reduction in the incidence of non-fatal cardiac complications (Fig 1) . The study attracted widespread criticism because patients who had already been prescribed long-term β-blocker therapy were included in the trial and, if randomised to the placebo arm, had their therapy abruptly stopped. In addition, only those patients who survived to hospital discharge were included in the fi nal analysis. Subsequent intention-to-treat analysis of the data demonstrated an insignifi cant difference in mortality rate at 2 years between the control and atenolol groups.
The DECREASE I study prospectively assessed the effect of perioperative bisoprolol, as compared with placebo, in patients undergoing major vascular surgery. Therapy was commenced, on average, one week preoperatively and continued for 30 days postoperatively. Importantly, the study protocol included a dose titration that was based on targeting a pre-defi ned heart rate range. The study demonstrated a clear reduction in mortality from cardiac causes and non-fatal myocardial infarction within 30 days of surgery (34% in the placebo group vs. 3.4% in the intervention group). A clear benefi t was demonstrated in the intervention group, and thus the trial was stopped early after enrolling only 112 patients. Once again, however, the trial design attracted several criticisms, including the failure to use a double-blinded methodology.
Encouraged by the results of DECREASE I, the same group of investigators undertook further trials. This family of studies statistically signifi cant reduction in myocardial infarction rates (4.2% metoprolol vs. 5.7% placebo), a reduced need for coronary revascularisation and a reduction in the number of patients developing atrial fi brillation. More importantly, however, there was a signifi cant increase in overall mortality (3.1% metoprolol vs. 2.3% placebo) and stroke (1% metoprolol vs. 0.5% placebo), as well as increased episodes of clinically signifi cant hypotension and bradycardia. The authors concluded that for every 1,000 patients undergoing non-cardiac surgery, metoprolol would prevent 15 myocardial infarctions, 3 coronary revascularisations and 7 patients' developing clinically signifi cant atrial fi brillation. Adversely, metoprolol would cause an excess of 8 patients to die and 5 to suffer a stroke for every 1,000 patients treated.
In spite of what appeared to be a well-conducted trial, the results were overshadowed by criticism of the dosing methodology employed. Trial protocols dictated that patients could potentially be prescribed a total of 400 mg of metoprolol ER on the day of surgery, a dose and formulation considered by many to be excessive for a 'β-blocker-naïve population'. The timing of the introduction of β-blocker therapy was also questioned. In line with other studies, the intervention commenced only 2-4 hours preoperatively, allowing little time for physiological adaption before the commencement of anaesthesia and surgery.
In 2009, the ACC/AHA downgraded their recommendations for perioperative β-blockade, stating 'In light of the POISE results, routine administration of perioperative beta blockers, particularly in higher fi xed-dose regimens begun on the day of surgery, cannot be advocated.' 9 Largely on the basis of the DECREASE family of studies and in contrast to the ACC/AHA downgrade, the European Society of Cardiology (ESC), proposed class 1 recommendations for the commencement of β-blockers in patients with signifi cant risk factors for atherosclerotic disease who are undergoing high-and intermediate-risk surgery. 10 In 2011, concerns were raised regarding the scientifi c credibility of data from the DECREASE VI trial and subsequent adjudication concluded that the DECREASE family of trials were conducted in a manner that was 'negligent and scientifi cally incorrect'. 11, 12 These discredited data were no longer valid and were considered unreliable evidence to continued to demonstrate the benefi ts of both bisoprolol and statins in intermediate-and high-risk non-cardiac surgery patients (Table 1) .
Despite the criticisms of these trials, the ground swell of support for perioperative β-blocker therapy led to the publication of the fi rst formal guidance on perioperative cardiovascular evaluation in non-cardiac surgery from the American College of Cardiology and the American Heart Association (ACC/AHA). 5 Based predominantly on the fi ndings of the McSPI and DECREASE trials, these guidelines cited class 1 recommendation for β-blocker therapy in patients with previous β-blocker use for hypertension, angina or arrhythmia, or for those deemed of high cardiac risk on preoperative cardiac testing.
By contrast, the fi rst negative trials questioning the role of β-blockers came in 2006 with the Diabetic Postoperative Mortality and Morbidity (DIPOM) 6 and Metoprolol after Vascular Surgery (MaVS) studies. 7 DIPOM randomised diabetic patients to placebo or sustained-release metoprolol, to be commenced 24 hours prior to surgery and continuing up to 8 days postoperatively. MaVS, a double-blinded randomised controlled trial, randomised patients to placebo or metoprolol, to begin 2 hours preoperatively and continuing for up to 5 days after surgery. Both trials titrated β-blocker therapy to heart rate and systolic blood pressure. The sample size of these combined trials (1,417 patients) surpassed that of the McSPI and DECREASE combined sample size by a factor of four. Both studies failed to demonstrate a signifi cant reduction in cardiovascular mortality in response to metoprolol, but found an increased incidence of hypotension and bradycardia requiring treatment in the metoprolol group.
In 2008, the Canadian-based Perioperative Ischemic Evaluation (POISE) 8 study was born out of an increasing scepticism and confl icting evidence regarding the benefi ts of perioperative β-blockers in non-cardiac surgery. This study was the largest of its kind and designed to be powered adequately to detect a 25% relative risk reduction in cardiovascular death or cardiac complications. The study enrolled 8,351 patients with or at risk of atherosclerotic heart disease and randomised them to placebo or extended release (ER) metoprolol immediately before 'high risk', non-cardiac surgery and continuing for 30 days postoperatively. Outcomes measured at 30 days showed a support the perioperative use of β-blocker therapy. The earlier DECREASE I study was not investigated as it had been carried out beyond the 10-year deadline for investigation. In 2013, the remaining studies on the preoperative use of β-blockers, excluding the discredited DECREASE studies, were subjected to a new meta-analysis. 13 The primary outcome examined in this analysis remained all-cause mortality at 30 days or at hospital discharge. On the basis of this new meta-analysis, the initiation of β-blockers preoperatively was associated with a 27% risk increase in 30-day all cause mortality (95% CI 1.01-1.60, p=0.04) and with reduced non-fatal myocardial infarction (relative risk reduction 0.73, p=0.001), but with increased risk of a cerebrovascular accident (CVA) (RR 1.73, p=0.05) and hypotensive episodes (RR 1.51, p<0.00001). The authors extrapolated that if current ESC guidelines were to be strictly adhered to in the UK, where almost 2.5 million intermediate-or high-risk procedures are carried out annually, there could be 10,000 potentially avoidable deaths in high-risk surgical patients in the UK.
Despite the discreditation of the DECREASE trial data in 2011, and this latest meta-analysis showing the potential harm in using perioperative β-blockers, the ESC have chosen to allow their 2009 class recommendations to remain in place until now.
14 The softening of their recommendations for initiation of perioperative β-blockade from class I to class IIb, with an insistence that this recommendation is underpinned by evidence that excludes the DECREASE I trial data, has been strongly contested recently.
15
Is there any role for perioperative β-blocker therapy?
Perhaps not surprisingly, the use of β-blockers in high-risk surgery has declined in recent times, 16 which may refl ect confusion within the perioperative medicine community regarding the evidence base on which to proceed.
Recently, evidence from both the perioperative and critical care community again shines a light on β-blocker therapy, suggesting that it may have an important role to play in improving outcomes.
In 2013, London et al 17 performed a retrospective, propensitymatched analysis of 136,745 patients from the American Veterans Affairs Surgical Quality Improvement (VASQIP) database who were treated over a 6-year period. This analysis demonstrated that among propensity-matched individuals, exposure to β-blockers on the day of or following major non-cardiac surgery was associated with lower rates of 30-day all-cause mortality, non-fatal Q-wave myocardial infarction and cardiac arrest. This fi nding was more likely in patients with two or more Revised Cardiac Index risk factors (ie in those with a high-risk surgery, cerebrovascular disease, ischaemic heart disease, congestive heart failure, diabetes mellitus, or renal insuffi ciency). Withdrawal of long-term β-blocker therapy in the perioperative period was associated with a higher mortality, similar to the fi ndings seen in DECREASE I for those patients using long-term β-blocker therapy who were randomised to the placebo arm of the trial. Interestingly, and contrary to the fi ndings of previous studies, no benefi t was seen in those patients undergoing vascular surgery -a group considered to be most at risk of signifi cant perioperative cardiac events and who might benefi t most from intervention. In contrast to POISE, this analysis was unable to demonstrate a higher risk of CVA with the exposure to β-blockers, which may refl ect the dosing strategy employed in the POISE trial.
Observational data from both those with severe brain injury and critically ill trauma patients has demonstrated that premorbid β-blocker use is associated with decreased hospital mortality. 18, 19 In critical illness, β-blockers are considered by many to have potential as an attractive intervention. The evidence is largely experimental and evolving, but there is renewed interest in their role in the treatment of sepsis, where overwhelming sympathetically mediated catecholamine excess may lead to direct myocardial damage. In a population of patients with septic shock, 20 esmolol intervention was associated with an increase in 28-day survival when used in titration to target a heart rate of 80-94 beats per minute. The treatment group had an increased stroke volume and a reduction in the dose of exogenous vasopressor, and maintained blood pressure without the need for additional inotropic support. The authors postulated that improved coronary fi lling time and intracellular calcium handling contributed to reduced cardiac work and myocyte toxicity, providing potential mechanisms for improved outcome. In a re-examination of the evidence for β-blocker use in sepsis, Novotny et al 21 highlight the potential noncardiac effects of β-blockers, including their effects on cytokine production, the infl ammatory cascade and improved cellular metabolism and effi ciency. Such fi ndings raise interesting questions about the utility of β-blockade in other infl ammatory illnesses, including recovery from surgery. If the presumed physiological responses to therapy have a 'protective' role to play in perioperative outcomes, it is conceivable that starting a 'onesize fi ts all' therapy at time of surgery, without a period of host modulation or adaption, might not be optimal.
Conclusions
The role of β-blockers in reducing the risk of major adverse cardiac events in high-risk patients undergoing non-cardiac surgery is unclear and fundamental questions remain unanswered. The timing and dose of intervention, the optimal selection of drugs based on pharmacodynamics, the appropriate outcomes to be measured and, not least, the population most likely to benefi t from treatment remain important factors that can only be answered by a new large well-conducted randomised control trial. The use of β-blockers in critically ill patients has provided exciting observations, which may challenge our understanding of pathophysiology and the mechanisms by which therapy might alter outcomes. Ultimately, a position of professional equipoise over the use of β-blockers in the perioperative period should drive a process of further investigation through more appropriate trial design. ■
